Malvern Instrument?s Announces Guest Presenter for March 18th Protein Characterisation Webinar
Malvern Instruments welcomes Prof. Dr. John F. Carpenter, from the University of Colorado Center for Pharmaceutical Biotechnology, as a guest presenter contributing to the company’s current series of webinars.
Professor Carpenter is a renowned expert in mechanisms for protein degradation and stabilization in pharmaceutical formulations. In his webinar on 18 March 2014 he will discuss how the combination of dynamic light scattering technology with Raman spectroscopy delivers new insights into the measurement and prediction of protein stability, aggregation and high order structure.
The non-invasive and non-destructive determination of numerous physicochemical properties of protein therapeutics and their aggregates is critical for developing formulation conditions that enhance product efficacy, stability and manufacturability. To meet the analytical challenges in early stage development, where the amount of material is limited, tools that measure very small volumes are also highly desirable.
In his webinar presentation, Prof. Carpenter will describe the combination of two established analytical techniques, dynamic light scattering (DLS) and Raman spectroscopy. Together they can be used to derive structural, thermodynamic and kinetic insights into the mechanisms of protein aggregation and the factors that influence protein stability. He will present a number of examples using model systems and manufactured biopharmaceutical products to illustrate the synergies of the two techniques and the new insights afforded by the combined approach.
Looking forward to the webinar, Dr Lisa Newey-Keane, Biopharmaceutical Portfolio Manager for Malvern, said: “We are delighted that Prof. Carpenter has agreed to talk about the work that he has been doing and to describe the use of a combined DLS/Raman Spectroscopy approach to protein characterization. His expertise in protein systems, especially in biopharmaceutical formulations, will provide a highly informative backdrop to the combined application of these two techniques and the examples he plans to describe will put this into the context of solving real-world problems.”
Prof. Dr John F. Carpenter is an expert in mechanisms for protein degradation and stabilization in pharmaceutical formulations, during bioprocessing and in delivery systems. He has published more than 200 peer-reviewed papers and is an inventor on 19 issued patents. He is Editor for Reviews and Commentaries for Journal of Pharmaceutical Sciences and serves on the Editorial Advisory Boards for various pharmaceutical journals.
Webinar registration is free and is open to all as part of Malvern’s continuing programme of information and education. For further details and to register, please visit www.malvern.com/dlsraman
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...